Eugene Kennedy
Technik-/Wissenschafts-/F&E-Leiter bei CARISMA THERAPEUTICS, INC.
Vermögen: - $ am 30.04.2024
Profil
Eugene P.
Kennedy is currently the Chief Medical Officer at Carisma Therapeutics, Inc. He previously held positions as an Associate Professor-Surgery at Thomas Jefferson University from 2006 to 2013, Vice President-Clinical & Medical Affairs at NewLink Genetics Corp.
from 2014 to 2017, and Chief Medical Officer at Lumos Pharma, Inc. from 2013 to 2021.
He also served as a Trustee at The Hope Funds for Cancer Research.
Additionally, he was the Chief Medical Officer at Innovative Cellular Therapeutics, Inc. and Galera Therapeutics, Inc. from 2022 to 2023.
Dr. Kennedy obtained his undergraduate degree from the University of Virginia and his doctorate from the Medical College of Virginia.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 25.02.2023 | 0 ( -.--% ) | - $ | 30.04.2024 |
Aktive Positionen von Eugene Kennedy
| Unternehmen | Position | Beginn |
|---|---|---|
| CARISMA THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 02.05.2024 |
Ehemalige bekannte Positionen von Eugene Kennedy
| Unternehmen | Position | Ende |
|---|---|---|
| GALERA THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.09.2023 |
| LUMOS PHARMA, INC. | Technik-/Wissenschafts-/F&E-Leiter | 06.03.2021 |
| Thomas Jefferson University | Corporate Officer/Principal | 01.12.2013 |
| Innovative Cellular Therapeutics, Inc. | Technik-/Wissenschafts-/F&E-Leiter | - |
The Hope Funds for Cancer Research
 The Hope Funds for Cancer Research Miscellaneous Commercial ServicesCommercial Services The Hope Funds for Cancer Research provides funds for cancer research. The private company is based in Newport, RI. The company was founded by Leah Rush Cann. | Direktor/Vorstandsmitglied | - |
Ausbildung von Eugene Kennedy
| University of Virginia | Undergraduate Degree |
| Medical College of Virginia | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| GALERA THERAPEUTICS, INC. | Health Technology |
| LUMOS PHARMA, INC. | Health Technology |
| CARISMA THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
NewLink Genetics Corp.
 NewLink Genetics Corp. Pharmaceuticals: MajorHealth Technology NewLink Genetics Corp. is a late-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of novel immunotherapeutic products to improve cancer treatment options for patients and physicians. The firm's portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a range of oncology indications. It products include HyperAcute Pancreas, HyperAcute Lung, HyperAcute Melanoma, HyperAcute Imunotherapies, NLG8189, and IDO Pathway Inhibitors. The company was founded by Charles J. Link and Nicholas N. Vahanian on June 4, 1999 and is headquartered in Ames, IA. | Health Technology |
The Hope Funds for Cancer Research
The Hope Funds for Cancer Research Miscellaneous Commercial ServicesCommercial Services The Hope Funds for Cancer Research provides funds for cancer research. The private company is based in Newport, RI. The company was founded by Leah Rush Cann. | Commercial Services |
| Innovative Cellular Therapeutics, Inc. |
